clinical development

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.

Amphista Therapeutics appoints new CEO and CMO ahead of planned AMX-883 IND application in April 2026 for acute myeloid leukemia treatment.

R1 Therapeutics raised $77.5M in oversubscribed Series A funding to advance AP306, a first-in-class treatment for hyperphosphatemia in chronic kidney disease patients.

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.

Lifeward gains shareholder approval for strategic Oramed deal, securing up to $47M capital while expanding into oral delivery technology.

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.

Moleculin Biotech releases CEO update on Phase 3 MIRACLE trial evaluating Annamycin for relapsed/refractory acute myeloid leukemia, with enrollment progressing on schedule.

$VERX surges 6.3% after kidney drug povetacicept achieves Phase 3 trial success with 52% proteinuria reduction, positioning FDA approval by year-end.

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.

BioRestorative Therapies will exhibit at Be+Well Beauty and Wellness Show in NYC (March 8-10, 2026) to advance its BioCosmeceutical platform commercialization.

Can-Fite's namodenoson meets primary safety endpoint in Phase IIa pancreatic cancer trial with no new safety signals; survival data pending.

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

Medidata secures top 'Luminary' AI rating from Everest Group, supporting 80% of FDA approvals with up to 37% faster patient enrollment.

Absci appoints Vertex Pharma veteran Dr. Ransi Somaratne as Chief Medical Officer to lead clinical development of AI-designed therapeutics, signaling execution focus.

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.